ArticleDermatology reports2025

Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis.

Paolo Dapavo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.